Lozano Fernández R
Arzneimittelforschung. 1983;33(7A):1073-80.
A drug surveillance study has been carried out with oral cytidine diphosphate choline (CDP-choline, citicoline, Somazina) in 2817 patients of all ages, predominating those between 60 and 80 years old. They were suffering from several neurological processes, mainly the vasculocerebral insufficiency and senile involution. Treatment was carried out for between 15 days and 2 months, the mean dose being 6 ml/d. The efficacy of the treatment was determined on the basis of the disappearance, improvement or worsening of clinical manifestations, most frequently shown by patients. The most benefited clinical manifestations by the treatment were: dizziness disappearing in 48.4% of the cases, and improving in 25.2%, cephalea disappearing in 46.5% and improving in 26.7%, insomnia with 38.6% and 24.9%, respectively; depression with 36.9% and 24.1% and memory shortage with 21.2% and 44.7% respectively. The best results were obtained in chronic cerebrovascular insufficiency, the improvements obtained in dizziness, cephalea, insomnia, fatigue and speech troubles being the most important. The safety of the drug was excellent since side effects were observed only in 5.01% of the patients. Among these effects, the most frequently seen were digestive troubles, observed in 3.6% of the cases.
一项针对口服胞二磷胆碱（CDP-胆碱、胞磷胆碱、索玛齐纳）的药物监测研究在2817名各年龄段患者中开展，其中60至80岁的患者居多。他们患有多种神经疾病，主要是脑血管供血不足和老年退化。治疗持续15天至2个月，平均剂量为6毫升/天。根据患者最常出现的临床表现的消失、改善或恶化情况来确定治疗效果。治疗最受益的临床表现为：头晕在48.4%的病例中消失，25.2%有所改善；头痛在46.5%的病例中消失，26.7%有所改善；失眠分别为38.6%和24.9%；抑郁分别为36.9%和24.1%；记忆力减退分别为21.2%和44.7%。在慢性脑血管供血不足方面取得了最佳效果，头晕、头痛、失眠、疲劳和言语障碍方面的改善最为显著。该药物的安全性极佳，因为仅5.01%的患者观察到副作用。在这些副作用中，最常见的是消化系统问题，在3.6%的病例中出现。
